Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group. 1991

R O Feneck
London, Chest Hospital, United Kingdom.

We studied 99 adult patients after elective cardiac surgery who had low cardiac output (cardiac index less than 2.5 L/min/m2) in spite of adequate cardiac filling pressure (pulmonary capillary wedge pressure less than 8 mm Hg). Patients received milrinone by loading dose (50 micrograms/kg over a 10-minute period), followed by a continuous infusion of either 0.375, 0.5, or 0.75 micrograms/kg/min (low-, middle-, and high-dose groups, respectively) given for a minimum of 12 hours. Patients were allocated to each dosage group sequentially, not randomly. Hemodynamic measurements were made before the loading dose and at 15, 30, 45, and 60 minutes, 3, 6, and 12 hours after the start of milrinone therapy. Further measurements were made at 2 and 4 hours after treatment was stopped. Milrinone therapy was associated with a rapid, well-sustained, and highly significant increase in cardiac index in all three dose groups (p less than 0.001), and a similar fall occurred in pulmonary capillary wedge pressure in all groups (p less than 0.001). Significant increases occurred in heart rate in all three groups (p less than 0.001). Systemic and pulmonary vascular resistance also fell significantly, although changes in this latter parameter were less predictable and more dose dependent. Few serious treatment-related adverse effects were seen. We conclude that intravenous milrinone is an effective and safe therapy for the treatment of low output states after cardiac surgery.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D002303 Cardiac Output, Low A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities. Low Cardiac Output,Low Cardiac Output Syndrome,Output, Low Cardiac
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

R O Feneck
January 1992, European journal of anaesthesiology. Supplement,
R O Feneck
April 2004, International journal of clinical pharmacology and therapeutics,
R O Feneck
July 2023, Journal of cardiothoracic and vascular anesthesia,
R O Feneck
April 1994, British journal of anaesthesia,
R O Feneck
April 2012, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue,
Copied contents to your clipboard!